Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RG 6129

Next Previous
Drug Profile

RG 6129

Alternative Names: RG-6129; RO-7444973

Latest Information Update: 17 Aug 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 02 Aug 2023 Hoffmann-La Roche terminates a phase I trial in Solid tumours (Inoperable/Unresectable, Metastatic disease) in Australia, Belgium, Denmark, Spain, USA and United Kingdom due to program discontinuation (NCT05129280)
  • 26 Apr 2023 Discontinued - Phase-I for Solid tumours (Inoperable/Unresectable, Metastatic disease) in USA, Spain, Australia (IV), prior to April 2023 (Roche pipeline, June 2023)
  • 26 Apr 2023 Discontinued - Phase-I for Solid tumours (Inoperable/Unresectable, Metastatic disease) in Belgium (IV), prior to April 2023 (Roche pipeline, June 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top